On the other hand, the development of HER2 targeting agents have remarkably improved prognosis in HER2 positive breast cancer, and novel agents such as antibody–drug conjugates (ADCs) are showing improved results [3,6,7]. This evidence concerns the gene ERBB2 and breast carcinoma.